References
- Peetermans M, Pollack C Jr, Reilly P, et al. Idarucizumab for dabigatran overdose. Clin Toxicol. 2016. [Epub head of print]. doi: http://dx.doi.org/10.1080/15563650.2016.1187737.
- Bouchard J, Ghannoum M, Bernier-Jean A, et al. Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. Clin Toxicol. 2015;53:156–163.
- Vlad I, Armstrong J, Ridgley J, et al. Dabigatran deliberate overdose: two cases and suggestions for laboratory monitoring. Clin Toxicol. 2016. [Epub ahead of print]. doi: http://dx.doi.org/10.3109/15563650.2015.1126287.
- Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy). J Am Coll Cardiol. 2014;63:321–328.
- Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–520.
- Stöllberger C, Pommer P, Schneider B, et al. Concerns about idarucizumab for dabigatran reversal. Blood Coagul Fibrinolysis. 2016;27:473–474.